Solventum
Price: 80.94Company and Business Model
Solventum operates in the healthcare sector, focusing on the development and commercialization of innovative medical solutions. Its core products include advanced therapeutic devices and diagnostic tools aimed at improving patient outcomes. The company generates revenue primarily through product sales and partnerships with healthcare providers and institutions. Solventum's business segments encompass research and development, manufacturing, and distribution of healthcare technologies.
Investment Profile
The investment profile of Solventum is more aligned with growth investors, given its focus on innovation and potential for revenue expansion. The company shows stable earnings growth and a moderate risk profile, appealing to those seeking capital appreciation. Its performance metrics suggest a favorable outlook for long-term investment strategies.
Fundamental metrics (experimental)
- EPS (TTM) — earnings per share for the last 12 months, $
- 8.21 OK
- Revenue QoQ — quarter-over-quarter revenue growth
- 0.5% ≈
- EPS surprise
- 9.6% better than expected
- 20d volatility
- 2.1% stable
Forecast impact
played outTrack in portfolio
Price chart
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-06-10 00:49 | Hold | Buy | Strong momentum and positive EPS surprise indicate growth potential. |
| 2026-06-09 02:51 | Buy | Hold | Mixed performance and uncertain market conditions. |
| 2026-06-05 02:48 | Hold | Buy | Strong momentum and solid EPS growth support bullish outlook. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-06-01 11:15 | Jefferies | Target Raised | — → 43 | 74.95 |
| 2026-05-15 11:13 | Wedbush | Update | — → 94 | 74.42 |
| 2026-05-06 13:34 | UBS | Target Lowered | 82 → 78 | 71.355 |
Nothing yet